The Inflation Reduction Act and Access to High-Cost Cardiovascular Therapies

Dhruv S Kazi; Rishi K Wadhera; Benjamin N Rome

doi:10.1001/jama.2023.19129

The Inflation Reduction Act and Access to High-Cost Cardiovascular Therapies

JAMA. 2023 Nov 7;330(17):1619-1620. doi: 10.1001/jama.2023.19129.

Authors

Dhruv S Kazi^{1

2}, Rishi K Wadhera^{1

2}, Benjamin N Rome^{2

3}

Affiliations

¹ Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 37728949
DOI: 10.1001/jama.2023.19129

No abstract available

Plain language summary

This Viewpoint discusses how the price negotiation for certain drugs under the Inflation Reduction Act will provide a unique opportunity to enhance access to therapies for older patients with cardiovascular conditions and diabetes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / economics
Drug Costs* / legislation & jurisprudence
Health Services Accessibility* / economics
Health Services Accessibility* / legislation & jurisprudence
Inflation, Economic* / legislation & jurisprudence
United States